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Background:  Mechanisms underlying heart failure with preserved ejection fraction (HFpEF) are poorly understood. We sought to provide 
insight into HFpEF disease pathogenesis by comparing metabolomic profiles between patients with HFpEF, heart failure with reduced 
ejection fraction (HFrEF) and normal controls.
methods:  Targeted, quantitative mass spectrometry-based measurement of 69 metabolites was performed on fasting plasma from 2,645 
individuals enrolled in the CATHGEN biorepository. HFpEF was defined as NYHA class II-IV symptoms within the preceding two weeks of 
sample collection and ejection fraction (EF)≥50%; HFrEF was defined as NYHA class II-IV symptoms and EF<50%; normal controls had no 
heart failure and EF≥50%. Principal components analysis was used for multidimensional data reduction and PCA-derived factor levels were 
compared across groups with ANCOVA and Bonferroni-corrected post-hoc t-tests.
results:  ANCOVA revealed significant differences between the three groups with respect to five PCA-derived factor levels after 
adjustment for multiple comparisons at the level of 14 factors (p<0.0035): long-chain dicarboxylacylcarnitines (p<0.001), long-chain 
acylcarnitines (p<0.001), ketone-related (p<0.001), and very long chain acylcarnitines (C22, p<0.001). Mean levels of all factors were 
highest in HFrEF, intermediate in HFpEF and lowest in the normal control group, except for C22 acylcarnitine, which was similar and lower 
in the heart failure cases than in the normal controls.
conclusion:  Using targeted, quantitative metabolomic profiling, we have identified novel biomarkers for HFpEF that report on 
mitochondrial function. These results could highlight mechanisms for HFpEF and potentially identify high-risk subtypes.
